Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)
Go back to Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)| IRONWOOD PHARMA-A (NASDAQ: IRWD) | Delayed: 3.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.82 | 52 Week High | $16.89 | |||
| Open | $3.82 | 52 Week Low | $7.35 | |||
| Day High | $3.82 | P/E | N/A | |||
| Day Low | $3.82 | EPS | $-2.35 | |||
| Volume | 24,042 | |||||
